Kornimate/medical-research-clean huggingface dataset:
third molar clinical trials: pericoronitis studies

Conditions: Pericoronitis

Summary: the purpose of this research study is to find out if the infection around 3rd molars and the resulting inflammation around the gum also produces a general systemic inflammation.

relate signs and symptoms of mild pericoronitis, an oral clinical condition characterized by intense inflammation and pain around a lower 3rd molar, to indicators of oral and systemic inflammation in patients seeking treatment for the condition.

Eligibility criteria:
inclusion criteria: * mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar (spontaneous pain with localized swelling, purulence/drainage) with recommended treatment being removal of 3rd molars, * age 18 - 35 years, * asa i, ii health status, * aap 1-3 periodontal status, * willingness to participate in the study, * geographic proximity to unc. exclusion criteria: * major signs/symptoms of pericoronitis (temperature \>101 , dysphagia, limited mouth opening \<20mm incisor, facial swelling/cellulitis, severe uncontrolled discomfort), * asa iii, iv health status, * medical contraindication to full mouth periodontal probing, * aap 4 periodontal status, * antibiotic treatment within the past 2 months, * current tobacco use, * bmi \> 29, * pregnancy, * non english speaking.

Keywords: pericoronitis periodontal
short-term and long-term outcomes of colorectal cancer treated with natural orifice specimen extraction surgery : a national registry-based study

Conditions: Colorectal Cancer

Summary: natural orifice specimen extraction surgery (noses) has gained widespread recognition among scholars and has gradually been promoted and popularized around the world. however, the development of noses is still in the exploratory stage and there is a lack of strong evidence from evidence-based medicine to support its feasibility and safety, which has greatly affected its clinical application and development. based on this, at the call of professor xishan wang, the chinese noses alliance conducted a large retrospective clinical study involving multiple centers. by summarizing the noses cases of nearly 100 centers in china, the study aims to clarify the current status of noses surgery in china. additionally, a comprehensive analysis and summary was conducted by combining the basic information of noses patients, perioperative data, postoperative pathological data, and follow-up information to further demonstrate the safety and feasibility of noses in the treatment of colorectal cancer. this study also provides more real and objective evidence-based medicine support for the promotion and development of noses surgery.


Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of primary malignant tumor in the colon or rectum; 2. the surgery meets the definition in the "consensus of noses experts in colorectal cancer"; exclusion criteria: 1. postoperative pathological diagnosis does not belong to primary malignant tumors in the colon or rectum; 2. the surgery does not meet the definition in the "consensus of noses experts in colorectal cancer".

Keywords: colorectal cancer natural orifice specimen extraction surgery minimally invasive surgery
hematoma block for reduction of distal radius fractures

Conditions: Fractures of the Distal Radius

Summary: the purpose of this study is to prove that injection of 15 to 20 ml of lidocaine 1% into the fracture site (hematoma block) is more effective in terms of pain relieving then injection of 10 ml of lidocaine 2%, and equally safe in terms of complications, for closed reduction of distal radius fractures.


Eligibility criteria:
inclusion criteria: * patients with fractures of the distal radius, with or without ulna fracture exclusion criteria: * children, * pregnant women, * patients with infection or suspected infection on the site for injection. * patients whose condition requires general anesthesia (patients with more fractures other than the distal radius and ulna, patients with many damage...)

Keywords: fractures of the distal radius hematoma block lidocaine
effect of g-csf on mdsc and cancer stem-cells interactions in non-small cell lung cancers (circuit)

Conditions: Non Small Cell Lung Cancer; Immunotherapy; Granulocyte Colony Stimulating Factor

Summary: immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (csc)) mechanisms. csc are able to circulate within blood, protected from destruction by immunosuppressive cells such as mdsc. some factors such as g-csf, administered to lower febrile neutropenia, should modulate properties of mdsc and csc, but data are contradictory, and literature remain poor regarding its effects on the interactions between mdsc and csc in blood clusters. indeed, this project aims at better characterizing the effect of g-csf on these interactions and on their functions in nsclc patients receiving g-csf.

mdsc, csc and the clusters in blood from nsclc patients will be assessed to evaluate the impact of g-csf on their phenotype and functions. samples from 2 groups of nsclc patients receiving chemotherapy and immunotherapy will be used: 15 receiving concomitant g-csf, and 15 not receiving concomitant g-csf

Eligibility criteria:
inclusion criteria: * patients (male or female) aged ≥ 18 years * histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy * receiving chemotherapy and immunotherapy as first-line treatment * signed written informed consent (no later than the day of inclusion, and before the blood sample collection) * patient affiliated or beneficiary to a health security system; exclusion criteria: * patient with a small cell lung carcinoma * non-metastatic disease * actionable mutation or genomic alteration in egfr, alk or ros1 * corticosteroids \> 10 mg/j * autoimmune disease * active and uncontrolled hiv infection * concomitant cancer * pregnancy or lactating women * psychiatric or medical conditions that prohibit the understanding and rendering of informed consent * patient under a legal protection measure * patient with a deprived liberty condition * patient incapable of giving signed informed consent * patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project

Keywords: non-small cell lung cancer immunotherapy myeloid-derived suppressor cells granulocyte-colony stimulating factor
safety and efficacy of biphasic remogliflozin etabonate in the treatment of type 2 diabetes

Conditions: Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2

Summary: this is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of a biphasic formulation of remogliflozin etabonate compared to placebo, administered over 12 weeks in subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * able to provide written informed consent * subject with clinical diagnosis of type 2 diabetes * hba1c 7.0 - 10.5% inclusive at visit 1. exclusion criteria: * history of metabolic acidosis or ketoacidosis. * current active renal disease that is not related to hypertension or type 2 diabetes (e.g. non-diabetic glomerulonephritis, interstitial nephritis, symptomatic nephrolithiasis, etc.) * use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is longer) prior to visit 1.
trial of safety nets in hospitalized patients

Conditions: Delirium; Agitated Behavior; Alcohol Withdrawl; Acute Confusional State; Acute Psychosis

Summary: this study compared standard hospital restraints to a newer safety net restraint system to compare them for acceptability, tolerance, duration of restrain, length of stay in the hospital, and satisfaction of md, nurse, and relatives of patients.


Eligibility criteria:
inclusion criteria: 1. age more than 18 2. hospitalized 3. acute confusion or agitation exclusion criteria: 1. patients who require acute respiratory or cardiac support such as patients requiring ventilator support or patients in cardiac or septic shock 2. patients who have a documented history of claustrophobia 3. patients or family members who refuse to consent for safety net treatment under any circumstances. failure to obtain consent due to absence of or inability to reach a family member or to give consent to participate in the study 4. failure to obtain consent due to absence of or inability to reach a family member within reasonable time or to give consent to participate in the study. 5. acutely ill patients requiring intravenous vasopressors, intubation or ventilatory support 6. other conditions deemed terminal within 24 hours as determined by the patient's attending physician 7. patients who stay less than 24 hours in the hospital 8. if patient is already on restrains for more than 48 hours preceding enrollment. 9. if two or more limbs are already on restraint to protect iv lines. 10. extreme degree of agitation requiring continuous iv sedation or anesthesia. such patients may pose a danger to staff or themselves if their restraints were to be discontinued in order to put them on study restraints. 11. when the intent of single wrist restraint is only to hold the iv line and patient is not agitated or in delirium.
efficacy of unstable shoes for instability and lumbopelvic pain

Conditions: Lumbopelvic Postpartum Pain

Summary: during pregnancy, pregnant women adopt an atypical pattern position with the intention to maintain stability and balance.these postural changes can cause instability at the level of the sacroiliac joint with painful condition during pregnancy and postpartum. 40 % of women have postpartum lumbopelvic instability. in 17 % of cases the lumbopelvic pain is perpetuated. another alteration influenced by the gestational status and progress of labor is urinary incontinence (ui). the mechanism developed by masai barefoot technology (mbt) provides an unstable base. some studies reviewed, indicate that this shoe increases muscle activity, contributes to the decrease of joint overload and thereby, decreases pain. objective to compare the efficacy of shoes with unstable sole mbt®, over the use of conventional sports shoes, in primiparous women with lumbopelvic postpartum pain. material and methods randomized clinical trial. 24 postpartum women from the gynecology service of the hospital universitario madrid chiron were included in the study. the subjects were randomly divided into experimental and control group.


Eligibility criteria:
inclusion criteria: primparous women. * postpartum, between 8-12 weeks after the date of delivery. * with lumbopelvic pain and positive diagnostic tests of sacroiliac pain * women with ambulation ability. exclusion criteria: * presence of vaginal prolapses. * be receiving another treatment for the alteration that concerns us, pharmacological or any other type of therapy. * neuromuscular alterations.
scn2a polymorphisms are associated with response to valproic acid in paediatric population(pakistan)

Conditions: Epilepsy

Summary: the goal of this observational study was to identify the effect of scn2a gene polymorphism in the paediatric epileptic pakistani population. the main question it aims to answer is: to evaluate the effect of this genetic polymorphism on the clinical efficacy of valproic acid participants were prescribed valproic acid after diagnosis of epilepsy.

this observational study aimed to identify the effect of scn2a rs2304016 gene polymorphism in the paediatric epileptic population. the main question it aims to answer is: • to evaluate the effect of this genetic polymorphism on the clinical efficacy of valproic acid the participants' blood samples were taken and further genotyping was performed using conventional tetraarms pcr. the results were visualized by gel electrophoresis.

Eligibility criteria:
inclusion criteria: * epileptic pakistani individuals of age between 1 to 12 years of either sex * each patient had experienced two or more clinically confirmed, spontaneous epileptic seizures in the past. * newly diagnosed patients started vpa 20 mg/kg (drug of the same brand was used for every patient throughout the study). exclusion criteria: * patients taking any other anti-epileptic drug. * patients taking medications that interact with vpa. * patients with moderate or severe systemic diseases
cadonilimab plus folfoxiri and bevacizumab as first line therapy for metastatic mss colorectal cancer

Conditions: Colorectal Cancer

Summary: cadonilimab is a first-in-class bispecific, humanized igg1 antibody targeting pd-1 and ctla-4, which has the potential to boost immune surveillance in tumors. this was a phase ii study of cadonilimab in combination with bevacizumab and folfoxiri as first line therapy for metastatic microsatellite stable (mss) colorectal cancer. the goal of this clinical trial is to evaluated the efficacy and safety.

cadonilimab is a first-in-class bispecific, humanized igg1 antibody targeting pd-1 and ctla-4, which has the potential to boost immune surveillance in tumors. this was a phase ii study of cadonilimab in combination with bevacizumab and folfoxiri as first line therapy in patients with metastatic microsatellite stable (mss) colorectal cancer. the goal of this clinical trial is to evaluated the efficacy and safety. cadonilimab (6mg/kg, iv, q2w, day1)+irinotecan\* 165 mg/m² iv continue for 1.5 hours, d1; oxaliplatin 85 mg/m² iv continue for 2 hours, d1; leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours, d1; 5-fu 2400 mg/m² cont. inf. 48h; repeat every 2 weeks (q2w) + bevacizumab （5mg/kg，d 1）

Eligibility criteria:
inclusion criteria: * patients with metastatic pmmr or mss colorectal adenocarcinoma. note: mmr or msi status will be performed locally by an immunohistochemistry (ihc) or pcr based test for eligibility. * patients who are naïve to systemic treatment in metastatic setting. * patients with previous neoadjuvant or adjuvant chemotherapy (that may have included oxaliplatin or investigational vegf inhibitors) are eligible if the treatment was completed \> 12 months before inclusion. * patients with the presence of at least one lesion with measurable disease as per recist 1.1 guidelines. lesions in previously irradiated areas should not be considered measurable unless they have clearly progressed since the radiotherapy. * patients have an eastern cooperative oncology group (ecog) performance status 0-1 exclusion criteria: * patients with msi-h colorectal adenocarcinoma as defined per local assessment using standard of care testing * patients with metastatic disease amenable to be resected with potentially curative surgery * patients who have received any systemic treatment for metastatic disease. * patients with a history of prior treatment with anti-pd-1, anti-pd-l1, anti-pdl2, anti-ctla-4 antibodies, other checkpoint inhibitors * patients who had received radiation within 14 days prior to the first dose of study drug
prevalence of positional nystagmus in a population of healthy adults

Conditions: Positional Nystagmus; Healthy Volunteers

Summary: to investigate the prevalence of positional nystagmus in a population of healthy danish adults.

open-label, cross-sectional prospective study examining the prevalence of positional nystagmus in healthy adults (adult with no previous or current inner ear disease) using a mechanical repositioning chair (trv-chair, interacoustics, middelfart, denmark). patients will undergo traditional testing related to positional nystagmus by means of both the dix-hallpike test and supine roll test (srt) bilaterally. latency, duration, and slow phase velocities will be registered and examiner as well as order of the positional tests performed with the trv chair will be block randomized.

Eligibility criteria:
inclusion criteria: * + 18 years exclusion criteria: * previous or current bppv, inner ear disease, other ear conditions or neurological conditions * reduced eye mobility * alcohol consumption within 48 hours * weight \> 150 kg. * known cerebral aneurysm * cerebral haemorrhage within 1 month * trouble cooperating during examinations * dhi-score \> 14
a phase 2, safety and efficacy of bemnifosbuvir (bem) and ruzasvir (rzr) in subjects with chronic hcv

Conditions: Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C; Hepatic Cirrhosis; HCV

Summary: this is an open-label trial to evaluate safety and efficacy of treatment with bem + rzr in subjects with chronic hcv infection.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent * male or female subjects between ≥ 18 years of age (or the legal age of consent per local regulations) and ≤ 85 years of age * female subjects of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to the use of an acceptable effective contraception * females must have a negative pregnancy test at screening and at day 1 prior to dosing * subjects must be direct-acting antiviral (daa)-treatment-naïve, defined as never exposed to an approved or experimental daa for hcv * documented medical history compatible with chronic hcv * liver disease staging assessment as follows: * absence of cirrhosis (f0 to f3) * compensated cirrhosis (f4) exclusion criteria: * female subject is pregnant or breastfeeding * co-infected with hepatitis b virus (hbv; positive for hepatitis b surface antigen \[hbsag\]) and/or human immunodeficiency virus (hiv) * abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator * prior exposure to any hcv daa * use of other investigational drugs within 30 days of dosing or plans to enroll in another clinical trial of an investigational agent while participating in the present study * subject with known allergy to the study medications or any of their components * history or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency * cirrhotic and has a child-pugh score \>6, corresponding to a child-pugh class b or c * history of hepatocellular carcinoma (hcc) or findings suggestive of possible hcc * any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
imr assessment in patients with new diagnosis of left ventricle dilatation

Conditions: Cardiomyopathies; Microcirculation; Microvessels

Summary: to establish if, in patients with new diagnosis of left ventricular dilatation without documentation at the coronary artery angiography of significant coronary artery lesions, there is a damage of the coronary microcirculation at the imr (index of microcirculatory resistance) assessment

the authors will enroll at the moment of coronary artery angiography patients without history of ischemic heart disease and new diagnosis (at transthoracic echocardiography) of left ventricular dilation. all patients will undergo coronary artery angiography. to be enrolled, it is necessary to have the absence of significant coronary artery stenosis (angiographic evaluation of the lesion \>40%) in all the vessels (main and side branch). the authors will proceed to perform the evaluation of the index of microvascular resistance (imr). the target vessel will be the left anterior descending artery. an intracoronary pressure/temperature sensor-tipped guidewire will be used. thermodilution curves will be obtained during maximal hyperemia. the imr will be calculated from the ratio of the mean distal coronary pressure at maximal hyperemia to the inverse of mean hyperemic transit time.

Eligibility criteria:
inclusion criteria: * new diagnosis of left ventricular dilation (dilatative cardiopathy) * absence of significant (\>40%) coronary artery disease at coronary artery angiography exclusion criteria: * history of ischemic heart disease * history of significant valvular disease * contraindication to hyperemic agent

Keywords: index of microvascular resistance
outcome after laparoscopic surgery for peptic ulcer perforation

Conditions: Intraabdominal Abscess After Procedure; Leakage; Pneumonia; Operation Wound; Infection

Summary: despite advances in laparoscopic surgery for perforated peptic ulcer (ppu), intra-abdominal abscess (iaa) is recognized as one of the commonly reported complications with relation to the extent of infectious abdominal contamination. herein, the investigators report their experience of laparoscopic surgery for ppu with/without peritoneal irrigation and discuss postoperative outcome. the investigators retrospectively examined the electronic medical records of the patients who underwent laparoscopic surgery for perforated peptic ulcer at a single medical center in taiwan between january 2013 and august 2021. retrospectively, the investigators would include those patients with clinical diagnosis of ppu who underwent emergent laparoscopic surgery. the patients with previous abdominal surgery, pathologic confirmed malignant ulcer perforation or concomitant ulcer bleeding were excluded. the investigators focused on post-operative complications and outcome after laparoscopic surgery with or without peritoneal irrigation. this information can be important in improving surgical options with respect to risk and potential benefits in this setting.


Eligibility criteria:
inclusion criteria: * the patients with clinical diagnosis of ppu underwent laparoscopic repair surgery. exclusion criteria: * the patients received surgery in an open approach or underwent laparoscopy initially but then intraoperatively converted to laparotomy.

Keywords: laparoscopic surgery perforated peptic ulcer peritoneal irrigation gauze wiping and suction intra-abdominal abscess